Aromatase is the enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). Without it, no estrogen is made. The CYP19A1 gene encodes aromatase and is expressed in multiple tissues — ovaries, bone, breast, brain, and adipose. rs4775936, located in a negative regulatory region¹¹ negative regulatory region
a promoter region that normally suppresses gene transcription of CYP19A1 (specifically exon I.6), influences how much aromatase is made in those tissues. Even modest changes in aromatase activity reshape the androgen-to-estrogen ratio across the body, with downstream effects on bone density, fertility, breast tissue, and how well aromatase-blocking drugs work.

The Mechanism

CYP19A1 is expressed from multiple tissue-specific promoters. The rs4775936 variant sits within the I.6 promoter region — a regulatory element that governs aromatase expression in bone and gonadal tissue. CYP19A1 lies on the minus strand of chromosome 15; the variant is C→T on the genomic plus strand (corresponding to G→A on the coding strand, which is why older papers describe it as an A/G polymorphism). The T allele appears to alter binding affinity for transcriptional repressors, modifying aromatase output in a tissue-specific manner. This promoter-level regulation — rather than a change in the aromatase protein itself — explains why the variant's effects are context-dependent, varying by tissue type, sex, age, and hormonal environment.

The Evidence

Bone mineral density. Enjuanes et al. studied 256 postmenopausal Spanish women²² Enjuanes et al. studied 256 postmenopausal Spanish women
Enjuanes A et al. A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone, 2006 and found that TT homozygotes had significantly higher lumbar spine bone mineral density compared to CC or CT individuals (p=0.029). Higher local aromatase activity in bone increases estradiol at the tissue level, which suppresses osteoclast-driven bone resorption — the likely mechanism.

Aromatase inhibitor response. Park et al. genotyped 46 CYP19A1 variants in 109 patients with hormone receptor-positive metastatic breast cancer on letrozole³³ Park et al. genotyped 46 CYP19A1 variants in 109 patients with hormone receptor-positive metastatic breast cancer on letrozole
Park IH et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes associated with letrozole. Cancer Chemother Pharmacol, 2011. The T allele of rs4775936 was associated with higher clinical benefit rate (OR 2.60, 95% CI 1.12–6.02, p=0.026). A larger retrospective study of 308 patients by Ferraldeschi et al. confirmed a trend⁴⁴ Ferraldeschi et al. confirmed a trend
Ferraldeschi R et al. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer. Breast Cancer Res Treat, 2012 (HR 0.79 per T allele, 95% CI 0.66–0.95, p=0.012), though the effect was attenuated after adjusting for disease extent and other prognostic factors.

Aromatase inhibitor-induced arthralgia. Borrie et al. prospectively followed 196 women initiating letrozole or anastrozole⁵⁵ Borrie et al. prospectively followed 196 women initiating letrozole or anastrozole
Borrie AE et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy. Breast Cancer Res Treat, 2020. More than 50% of the group experienced arthralgia, and rs4775936 was significantly associated with both developing arthralgia (adjusted p=0.016) and with discontinuing therapy due to intolerable joint pain. The same variant that may improve tumor response appears also to predispose to this debilitating side effect — likely through altered estrogen withdrawal kinetics in joint tissue.

Lipid effects. In 303 women on adjuvant aromatase inhibitors, Santa-Maria et al. identified rs4775936 as one of seven CYP19A1 variants linked to triglyceride reductions of 20.2–39.3 mg/dL⁶⁶ Santa-Maria et al. identified rs4775936 as one of seven CYP19A1 variants linked to triglyceride reductions of 20.2–39.3 mg/dL
Santa-Maria CA et al. Association of variants in candidate genes with lipid profiles in women on adjuvant aromatase inhibitor therapy. Clin Cancer Res, 2016 (p<0.00053), reflecting aromatase's role in modulating sex-hormone-sensitive lipid metabolism.

Cancer risk. A meta-analysis of 25,446 endometrial cancer cases and 41,106 controls found CYP19A1 rs4775936 associated with increased endometrial cancer risk⁷⁷ CYP19A1 rs4775936 associated with increased endometrial cancer risk
Das AP et al. Meta-analysis of 49 SNPs identifies polymorphisms in hormone regulation genes associated with endometrial cancer risk. Genes, 2023. In prostate cancer, Kanda et al. reported⁸⁸ Kanda et al. reported
Kanda S et al. Functional genetic polymorphisms in CYP19A1 and prostate cancer risk and survival. Int J Cancer, 2015 that the variant allele reduced prostate cancer susceptibility but correlated with shorter survival in metastatic disease — possibly through effects on the estrone/androstenedione ratio in the tumor microenvironment.

Practical Actions

People carrying one or two T alleles face a nuanced picture: potential protection in bone density, possible benefit in aromatase inhibitor treatment response, but elevated risk of AI-induced joint pain and need for proactive monitoring of hormone-sensitive tissue (endometrium, prostate). Given that this variant acts through tissue-specific promoter modulation, the downstream effects depend heavily on hormonal context — most pronounced in postmenopausal women (low circulating estrogens, maximal dependence on local aromatase) and during AI therapy (aromatase pharmacologically suppressed).

Women with breast cancer being considered for aromatase inhibitor therapy should ensure their oncology team is aware of this variant: it may inform both expected response and the likelihood of joint-pain-driven discontinuation. For postmenopausal women not on AI therapy, higher local aromatase activity in bone may confer modest skeletal protection — though this requires adequate calcium and vitamin D to be realized.

Interactions

rs4775936 sits within a CYP19A1 haplotype block with several other functional variants, including rs10046, rs700518, rs1062033, and rs767199. Combined haplotype analyses consistently show stronger associations than any single SNP alone, particularly for bone density and hormone levels. The variant also interacts with estrogen receptor alpha variants (ESR1) — ESR1 polymorphisms modulate sensitivity to aromatase-derived estrogens, so the combination of altered aromatase output (CYP19A1) and altered estrogen signaling (ESR1) can amplify or dampen phenotypic effects. Gene-environment interactions with fracture risk probability scores have been documented (PMID 41929826), suggesting clinical context mediates genetic risk substantially.

BLK (B-lymphoid tyrosine kinase)¹¹ BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells is a critical regulator of B-cell receptor signaling and B-cell tolerance. rs4840568 is a 2kb-upstream variant in the same FAM167A-BLK regulatory region as the more extensively studied rs13277113, and the two variants sit roughly 1.8 kilobases apart on chromosome 8p23.1. Multiple studies have genotyped both SNPs simultaneously; in Han Chinese populations they are in strong linkage disequilibrium²² strong linkage disequilibrium
LD r²>0.9 and D′>0.9, meaning the two alleles are nearly always inherited together in East Asian populations, per Yin et al. 2021 (PMID 34637583). Despite this LD, rs4840568 shows somewhat different allele frequencies across ancestries — particularly a higher A-allele frequency in African and Latino populations than rs13277113 — suggesting it may tag additional regulatory variation or capture LD with functional elements that rs13277113 does not fully represent in non-Asian populations.

The Mechanism

Like rs13277113, rs4840568 sits in the shared promoter/enhancer region upstream of the BLK transcription start site. Variants in this region collectively modulate BLK mRNA levels in B cells: the risk haplotype carrying A alleles at both rs4840568 and rs13277113 is associated with lower BLK expression in B-cell lines, measured directly in the 2008 discovery study³³ 2008 discovery study
Hom et al. 2008 — BLK mRNA reduced in B-cell lines from carriers of the risk haplotype. Reduced BLK kinase activity impairs the tolerance checkpoint that normally eliminates self-reactive B-cell clones in the bone marrow, allowing autoreactive B cells to survive and produce autoantibodies — the molecular driver of SLE, Sjögren's syndrome, and related diseases.

Whether rs4840568 has independent functional effects beyond tagging the rs13277113 risk haplotype has not been resolved in functional studies. The 2021 NMOSD study⁴⁴ 2021 NMOSD study
Yin et al. — 310 Han Chinese individuals; rs4840568 showed no independent association with neuromyelitis optica after haplotype conditioning found no independent rs4840568 signal after accounting for the broader haplotype. Nevertheless, the variant independently appeared in a multi-phenotype GWAS⁵⁵ multi-phenotype GWAS
Sakaue et al. 2021 — largest multi-trait GWAS to date, combining data across thousands of traits as a genome-wide significant hit for serum total protein levels (beta=+0.028, P=4×10⁻³³), consistent with altered immunoglobulin and immune protein output in risk-allele carriers.

The Evidence

The primary evidence anchor is the Zeng et al. 2017 meta-analysis⁶⁶ Zeng et al. 2017 meta-analysis
PMID 28885337 — 33 studies total; rs4840568 analysis covered 4 studies with 11,391 SLE cases and 10,972 controls, which found rs4840568 A allele OR=1.32 (95% CI 1.22–1.43) for SLE, comparable to the rs13277113 OR of 1.33 in the same paper. An earlier Chinese case-control study⁷⁷ Chinese case-control study
Chen et al. 2012 — 532 SLE cases, 576 controls; high-resolution melting genotyping found significant allele associations for both rs4840568 and rs13277113 in a Han Chinese cohort.

Beyond SLE, a Chinese AITD cohort⁸⁸ Chinese AITD cohort
Song et al. 2018 — 999 autoimmune thyroid disease patients (624 Graves' disease, 375 Hashimoto's thyroiditis) and 797 controls; adolescent-focused analysis found the A allele of rs4840568 linked to autoimmune thyroid disease susceptibility, extending the BLK locus associations beyond the traditional SLE/RA/Sjögren's disease spectrum.

The evidence base for rs4840568 specifically is thinner than for rs13277113 — four studies versus twenty-four — and the independence of the rs4840568 signal from the rs13277113 haplotype has not been established. Given the strong LD between the two variants in Asian populations, the practical clinical implication is similar: elevated background risk for B-cell-driven autoimmune disease, with monitoring as the primary action.

Practical Implications

Carriers of the A allele at rs4840568 are likely also carrying the A allele at rs13277113 in the same chromosomal segment, particularly if they are of Asian ancestry. The combined risk profile of the BLK locus — elevated in individuals with A alleles at multiple BLK region SNPs — centers on a modestly increased lifetime risk for systemic lupus erythematosus, and potentially for autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis). These are treatable conditions with excellent outcomes when detected early.

There are no proven dietary supplements or pharmacological preventions for BLK-mediated autoimmune predisposition. The actionable response is symptom awareness and access to appropriate screening.

Interactions

rs4840568 and rs13277113 are in strong LD (r²>0.9 in East Asian populations) and are likely co-inherited as part of the same BLK risk haplotype in most individuals. Their combined presence on a single chromosome is the unit of risk rather than independent additive contributions. The broader BLK-BANK1 interaction documented for rs13277113 is expected to apply equally to rs4840568 carriers, since the same haplotype block is implicated in both studies.

For individuals with rs4840568 AA genotype who also carry risk alleles at BANK1 rs10516487⁹⁹ BANK1 rs10516487
BANK1 R61H variant in B-cell scaffold protein; synergistic with BLK variants for Sjögren's syndrome risk (OR=2.36 combined), the combined risk for primary Sjögren's syndrome is substantially elevated beyond either variant alone.

Alpha-adducin is a cytoskeletal protein that does something quietly consequential in your kidney tubules: it controls how many sodium pumps sit active at the cell surface. The ADD1 gene (adducin 1)¹¹ ADD1 gene (adducin 1)
encodes the alpha subunit of the adducin heterotrimer, which links the spectrin-actin cytoskeleton to the plasma membrane and regulates ion transport channel trafficking in kidney cells. When adducin stabilizes the Na+/K+-ATPase²² Na+/K+-ATPase
the sodium-potassium pump that moves three sodium ions out of the cell for every two potassium ions in, establishing the electrochemical gradient that drives secondary sodium transport at the cell surface, more sodium gets reabsorbed from the tubular filtrate back into the bloodstream — raising blood volume and, with it, blood pressure.

The Gly460Trp variant substitutes tryptophan for glycine at position 460 in the protein's tail domain, altering how tightly the pump anchors. About 19% of Europeans carry at least one copy of the Trp allele; in East Asian populations the frequency climbs to 51%, which may partly explain higher rates of salt-sensitive hypertension in those populations.

The Mechanism

At position 460, the normal glycine (Gly) creates a flexible hinge in adducin's tail domain. Substituting tryptophan (Trp) — a bulkier, aromatic amino acid — rigidifies the structure and increases affinity for the Na+/K+-ATPase³³ increases affinity for the Na+/K+-ATPase
the Trp460 isoform stabilizes the pump at the apical membrane of renal proximal tubule cells, increasing its surface density and thus its total sodium transport capacity. More pumps at the surface means more tubular sodium reabsorption.

The consequence unfolds in two kidney compartments. In the proximal tubule, where most filtered sodium is reclaimed, Trp460 adducin increases baseline sodium reabsorption. When a salt load arrives — a salty meal, intravenous saline — the Trp460 kidney retains more of that sodium rather than excreting it, blunting the normal pressure-natriuresis response and causing a steeper, more prolonged blood pressure rise.

The Trp460 variant also impairs endothelial function. In the vasculature, adducin helps organize caveolae — the lipid-raft microdomains where endothelial nitric oxide synthase (eNOS) resides. Disruption of this organization reduces eNOS activation, blunting nitric oxide-dependent vasodilation and adding a vascular component to the hypertension risk.

The Evidence

The vascular consequences are documented in a study of 110 never-treated hypertensive patients⁴⁴ 110 never-treated hypertensive patients
Perticone et al., J Hypertens 2007. Trp allele carriers showed markedly impaired forearm blood flow response to acetylcholine — a test of endothelium-dependent vasodilation — rising only 269% at the highest dose versus 395% in Gly/Gly homozygotes (P<0.001). The response to sodium nitroprusside, which acts independently of the endothelium, was identical between groups, confirming that the deficit is specifically endothelial, not vascular smooth muscle.

Cardiovascular outcomes data come from the Rotterdam Study (6,471 participants)⁵⁵ Rotterdam Study (6,471 participants)
van Rijn et al., Stroke 2006, where Trp allele carriers had a stroke hazard ratio of 1.22 (95% CI 1.02–1.45), ischemic stroke HR 1.29 (95% CI 1.02–1.63), and myocardial infarction HR 1.33 (95% CI 1.05–1.69). Carotid intima-media thickness was modestly increased in carriers (0.80 vs 0.79 mm, P=0.04). Critically, the interaction between the Gly460Trp polymorphism and hypertension was statistically significant — the risk was amplified in those who were also hypertensive, linking the molecular sodium-retention mechanism to hard cardiovascular outcomes.

For pharmacogenomics, a meta-analysis of 4 studies (1,001 patients)⁶⁶ meta-analysis of 4 studies (1,001 patients)
Choi et al., Int J Clin Pharmacol Ther 2013 found that the GlyGly genotype achieved significantly greater blood pressure reduction on hydrochlorothiazide than TrpTrp homozygotes (standard difference 1.80, 95% CI 1.38–2.22). The sodium-retaining effect of Trp460 adducin partially offsets the diuretic's mechanism, which also targets tubular sodium transport.

A Ukrainian cohort study (2024)⁷⁷ Ukrainian cohort study (2024)
Sydorchuk et al., Endocr Regul confirmed that T-allele carriers in hypertensive patients had approximately 4-fold higher odds of being sodium-sensitive — women OR 4.71 (95% CI 1.92–11.56, P<0.001) and men OR 4.09 (95% CI 1.03–16.28, P=0.041).

Practical Actions

For Trp allele carriers — particularly TT homozygotes — the most actionable intervention is aggressive dietary sodium restriction. Unlike the general population, where blood pressure response to sodium reduction is variable, carriers of the Trp460 allele have a documented biological mechanism that makes sodium reduction disproportionately effective.

Hydrochlorothiazide, the most commonly prescribed first-line antihypertensive, works less well in Trp carriers because both the drug and adducin act on overlapping tubular sodium transport pathways. If hypertension requires pharmacotherapy, ACE inhibitors, ARBs, or renin-angiotensin-aldosterone system agents may be pharmacologically better matched to this genotype.

Monitoring endothelial function through blood pressure response tracking and periodic cardiovascular risk assessment is warranted for TT homozygotes, who face the combination of both renal sodium retention and impaired vasodilation.

Interactions

The ADD1 Trp460 allele functions as a permissive variant in the renal sodium handling network. A physiological interaction study involving ADD1 (rs4961), WNK1, and NEDD4L (rs1008899/rs4149601) found that the ADD1 Trp allele is required for the effects of the other variants to manifest — individuals carrying risk alleles at all three loci showed the most pronounced sodium retention, the highest blood pressure on saline loading (P=0.021), and the greatest response differential to thiazide therapy (P=0.008). This axis — ADD1 → WNK1 → NEDD4L → ENaC — represents a coherent sodium-retention pathway where each node amplifies the others' effects.

The interaction with endogenous ouabain (a naturally occurring Na+/K+-ATPase inhibitor circulating at low levels in plasma) is also documented: Trp460 carriers with elevated ouabain showed the largest blood pressure rises on volume loading, suggesting adducin-ouabain co-regulation of pump density.

Fibrinogen is the central protein of blood clot formation. When a vessel is damaged, thrombin cleaves fibrinogen into fibrin monomers that spontaneously polymerize into a mesh-like scaffold, which factor XIIIa then cross-links into a stable clot. The fibrinogen gamma chain (FGG)¹¹ fibrinogen gamma chain (FGG)
encoded by the FGG gene on chromosome 4q32; the gamma chain forms the outer D-domain of fibrinogen, which mediates the polymerization contacts between fibrin monomers plays a critical structural role in this process. rs6063 introduces an arginine in place of glycine at position 191 of the gamma chain — a change with measurable consequences for how fibrin clots form.

The Mechanism

The p.Gly191Arg substitution replaces a small, electrically neutral amino acid with a large, positively charged one in a region of the gamma chain involved in fibrin monomer-to-monomer contacts. This class of structural defect can disrupt the 'B:b' polymerization knob-hole interactions that drive fibrin assembly, resulting in abnormally structured clots²² This class of structural defect can disrupt the 'B:b' polymerization knob-hole interactions that drive fibrin assembly, resulting in abnormally structured clots
In dysfibrinogenemias caused by gamma-chain missense variants, the polymerization defect typically produces clots that are denser, have thinner fibers, and are more resistant to fibrinolytic breakdown compared to normal fibrin. Structurally abnormal fibrin clots are harder for plasmin to dissolve, shifting the hemostatic balance toward thrombosis.

ClinVar classifies the rs6063 T allele as pathogenic for Fibrinogen Milano XII in a digenic context — meaning this variant can act in concert with a second fibrinogen mutation to produce a named congenital fibrinopathy. In the heterozygous state (one T allele, one C allele), the abnormal gamma chain is incorporated into some fraction of circulating fibrinogen molecules, producing a quantitative but not complete disruption of normal fibrin assembly.

The Evidence

A prospective population-based cohort study (the Malmö Thrombophilia Study) genotyped common missense variants in fibrinogen genes in 1,465 VTE patients followed for approximately 10 years and 429 healthy controls³³ A prospective population-based cohort study (the Malmö Thrombophilia Study) genotyped common missense variants in fibrinogen genes in 1,465 VTE patients followed for approximately 10 years and 429 healthy controls
Memon AA, Zöller B, Svensson PJ, Sundquist J, Sundquist K. Fibrinogen genotypes and their impact on recurrence of VTE and family history. Br J Haematol. 2025;206(2):657-665.. rs6063 was significantly associated with primary VTE: OR 8.2 (95% CI 1.05–63.6) after adjustment for age and sex. The wide confidence interval reflects the rarity of the T allele (~0.5% globally) and the resulting small number of T carriers in even large cohorts — but the direction of effect is clear and statistically significant.

A 2024 multicenter analysis of 166 congenital fibrinogen disorder patients across 16 countries documented the clinical heterogeneity of dysfibrinogenemia⁴⁴ A 2024 multicenter analysis of 166 congenital fibrinogen disorder patients across 16 countries documented the clinical heterogeneity of dysfibrinogenemia
Mohsenian et al. found VTE rates around 10–11% across fibrinogen disorder subtypes, with striking obstetric impact in dysfibrinogenemic women (86% spontaneous abortion rate in affected pregnancies). FGG variants account for a meaningful proportion of dysfibrinogenemia cases.

Compound fibrinogen genotypes — where an index mutation interacts with common SNPs in the same or different fibrinogen genes — can amplify thrombogenic risk⁵⁵ Compound fibrinogen genotypes — where an index mutation interacts with common SNPs in the same or different fibrinogen genes — can amplify thrombogenic risk
Bor et al. 2022 demonstrated that fibrin structural measures (fiber thickness, mass-to-length ratios) explain thrombotic phenotype variation that neither the index mutation alone nor SNPs alone predict. This is consistent with the ClinVar digenic classification of Fibrinogen Milano XII: the pathogenic phenotype requires rs6063 together with a second fibrinogen-gene variant.

Evidence level is moderate: a large prospective cohort demonstrating a significant association (OR 8.2), supported by consistent mechanistic understanding of dysfibrinogenemia, but limited to a single primary study specifically addressing this rsID with a wide confidence interval due to variant rarity.

Practical Actions

T allele carriers — virtually all of whom are heterozygous CT — have elevated VTE risk and should be aware of high-risk situations: prolonged immobility (long flights, hospitalization), surgery, oral contraceptives or hormone replacement therapy, pregnancy, and dehydration. Anticoagulation decisions require clinical evaluation by a hematologist or thrombosis specialist; anticoagulation after a first unprovoked VTE is typically extended if a thrombophilic variant is confirmed.

The raw OR of 8.2 should be understood in context: the baseline lifetime VTE risk is roughly 5–8% in the general population, so elevated relative risk remains rare in absolute terms. Thrombotic risk is also modified by concurrent thrombophilic variants (Factor V Leiden, prothrombin G20210A), lifestyle factors, and body weight.

Interactions

rs6063 has been classified as pathogenic for Fibrinogen Milano XII in a digenic context — meaning a second fibrinogen-gene variant (in trans) is required for the full named phenotype. The Memon et al. 2025 study also examined rs6050 (FGA Thr312Ala) and rs2066865 (FGG 3' downstream), which may interact with rs6063 to amplify overall fibrinogen dysfunction and VTE risk.

Concurrent Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963) would compound thrombotic risk substantially — the intersection of a dysfibrinogenemia variant and an established thrombophilia warrants hematology evaluation rather than routine monitoring.

The low-density lipoprotein receptor (LDLR) is the primary gateway through which your liver removes cholesterol from the bloodstream. Mutations in this gene cause the majority of familial hypercholesterolemia cases¹¹ Mutations in this gene cause the majority of familial hypercholesterolemia cases
LDLR mutations account for 80-85% of FH, a condition causing severely elevated LDL from birth, leading to premature cardiovascular disease. While pathogenic LDLR mutations are rare, the common variant rs6511720 in intron 1 represents a subtler regulatory change that affects how efficiently the gene is expressed. This variant was identified in genome-wide association studies as a significant modulator of LDL cholesterol levels²² identified in genome-wide association studies as a significant modulator of LDL cholesterol levels
Beta = -0.22 for LDL-C, p = 3.85 × 10⁻²⁶² in the Global Lipids Genetics Consortium meta-analysis of 170,607 individuals and coronary heart disease risk.

The T allele at rs6511720 is present in approximately 11% of people of European descent, 13% of those of African descent, but only 1% of East Asians³³ 11% of people of European descent, 13% of those of African descent, but only 1% of East Asians
Population frequency data from dbSNP and gnomAD, making this a moderately common protective variant with substantial ethnic variation. Each copy of the T allele is associated with lower LDL cholesterol levels and reduced risk of coronary heart disease.

The Mechanism

The rs6511720 variant sits within intron 1 of the LDLR gene, 2,015 bases downstream of exon 1⁴⁴ intron 1 of the LDLR gene, 2,015 bases downstream of exon 1
HGVS nomenclature: c.67+2015G>T, in a region that functions as a regulatory enhancer. The T allele creates a binding site for serum response element (SRE) transcription factors⁵⁵ binding site for serum response element (SRE) transcription factors
Luciferase reporter assays in Huh7 hepatocellular carcinoma cells demonstrated allele-specific enhancer activity, which are proteins that amplify gene transcription in response to growth signals and sterol levels. When functional studies tested the two alleles in liver cells, the rare T allele increased LDLR promoter activity by approximately 29% compared to the common G allele.

This enhanced expression translates directly to more LDL receptor proteins on the surface of liver cells. With more receptors available, hepatocytes can capture and internalize more LDL particles from the bloodstream⁶⁶ capture and internalize more LDL particles from the bloodstream
The LDLR binds apolipoprotein B-100 on LDL particles, triggering receptor-mediated endocytosis, lowering circulating cholesterol levels. The effect is subtle but meaningful: each T allele reduces LDL cholesterol by roughly 4-5 mg/dL on average.

The variant is in complete linkage disequilibrium with three other intron-1 SNPs⁷⁷ complete linkage disequilibrium with three other intron-1 SNPs
Including rs57217136, rs141787760, and rs60173709, which together form a haplotype, meaning these variants are inherited as a unit. The haplotype's combined effect on LDLR expression is approximately 29%, with each variant contributing through distinct transcription factor binding sites.

The Evidence

The association between rs6511720 and LDL cholesterol has been replicated across multiple large genetic consortia⁸⁸ replicated across multiple large genetic consortia
Including the Global Lipids Genetics Consortium (N=170,607) and validated in multiethnic cohorts, establishing this as one of the well-characterized lipid-associated variants. The T allele is associated with lower LDL-C levels (beta = -0.22 standard deviations) and correspondingly lower risk of coronary heart disease (odds ratio approximately 0.89, representing about 12% reduced risk per T allele).

Beyond baseline cholesterol levels, rs6511720 also affects response to statin therapy⁹⁹ response to statin therapy
In the JUPITER trial of rosuvastatin, rs6511720 was associated with 2.6% greater LDL-C reduction per T allele (p=0.005). This makes pharmacogenomic sense: statins work by inhibiting cholesterol synthesis in the liver, which triggers compensatory upregulation of LDLR expression. Individuals who start with genetically higher LDLR expression (T carriers) may achieve greater absolute reductions when statins further amplify receptor levels.

The functional mechanism was confirmed through luciferase reporter assays demonstrating the T allele's 29% increase in LDLR transcription¹⁰¹⁰ luciferase reporter assays demonstrating the T allele's 29% increase in LDLR transcription
Huh7 cells transfected with T allele constructs showed significantly higher promoter activity, and electrophoretic mobility shift assays proved that the T allele specifically binds serum response element (SRE) transcription factors. These experiments bridge the gap between genetic association and biological mechanism.

Interestingly, another common LDLR variant, rs688 in exon 12, interacts with rs5925 to regulate LDLR splicing efficiency¹¹¹¹ rs688 in exon 12, interacts with rs5925 to regulate LDLR splicing efficiency
The four possible haplotypes show splicing efficiencies ranging from 68.5% to 79.6%, affecting the proportion of functional LDLR transcripts. While rs6511720 modulates transcription, rs688 affects post-transcriptional processing, illustrating how multiple regulatory layers fine-tune LDLR expression.

Practical Implications

For individuals with the common GG genotype, standard cardiovascular prevention guidelines apply. Current recommendations emphasize LDL cholesterol targets based on cardiovascular risk¹²¹² Current recommendations emphasize LDL cholesterol targets based on cardiovascular risk
For general prevention, LDL <100 mg/dL; for high-risk patients with established disease, <70 mg/dL; for very high-risk patients, <55 mg/dL. Diet, exercise, and when indicated, statin therapy, remain the cornerstones of cholesterol management.

Those carrying one or two T alleles have a genetic advantage in cholesterol clearance, but this doesn't negate the importance of healthy habits. Dietary interventions can powerfully modulate LDL levels regardless of genetics¹³¹³ Dietary interventions can powerfully modulate LDL levels regardless of genetics
Soluble fiber (5-10 g/day) reduces LDL by 5-10%, plant sterols (2 g/day) by 5-15%. The Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil¹⁴¹⁴ Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil
Multiple studies demonstrate LDL reductions of 8-15% with adherence to Mediterranean diet, has been consistently shown to reduce cardiovascular events independent of baseline cholesterol levels.

If statin therapy is prescribed, T allele carriers may achieve target cholesterol levels with lower doses or see greater absolute reductions at standard doses. However, dose adjustments should always be made based on measured lipid responses rather than genetic prediction alone. Guidelines recommend checking lipid panels 4-12 weeks after starting or adjusting statin therapy¹⁵¹⁵ Guidelines recommend checking lipid panels 4-12 weeks after starting or adjusting statin therapy
Repeated every 3-12 months to assess adherence and response, with dosing titrated to achieve individual risk-based targets.

Interactions

The rs6511720 variant is in complete linkage disequilibrium with rs57217136, rs141787760, and rs60173709¹⁶¹⁶ complete linkage disequilibrium with rs57217136, rs141787760, and rs60173709
These four intron-1 variants form a haplotype with combined effects on LDLR expression, meaning they are inherited together. The protective T allele at rs6511720 virtually always occurs with the minor alleles at these linked positions, and their combined regulatory effects produce the observed 29% increase in LDLR expression.

Beyond the LDLR locus, cholesterol metabolism involves a network of genes. PCSK9 (proprotein convertase subtilisin/kexin type 9) negatively regulates LDLR by promoting receptor degradation¹⁷¹⁷ PCSK9 (proprotein convertase subtilisin/kexin type 9) negatively regulates LDLR by promoting receptor degradation
Loss-of-function PCSK9 variants like rs11591147 increase LDL receptor levels and reduce cardiovascular risk. Conversely, gain-of-function PCSK9 variants like rs505151 accelerate LDLR degradation and raise cholesterol. Individuals carrying both protective LDLR variants (like rs6511720 T) and protective PCSK9 variants would experience compounded benefits, while those with risk alleles at both loci might face elevated cholesterol from dual mechanisms.

The rs688 variant in LDLR exon 12 affects splicing efficiency when paired with rs5925¹⁸¹⁸ rs688 variant in LDLR exon 12 affects splicing efficiency when paired with rs5925
The combined haplotype influences what proportion of LDLR transcripts are properly processed. Someone carrying the rs6511720 T allele (high transcription) but also the rs688 T allele (reduced splicing) might see attenuated benefits, as more transcripts are produced but fewer are successfully spliced into functional protein. Conversely, optimal LDLR function would result from combining high transcription (rs6511720 T) with efficient splicing (rs688 C, rs5925 C).

APOB variants affect the ligand that LDLR recognizes¹⁹¹⁹ APOB variants affect the ligand that LDLR recognizes
Rare pathogenic APOB mutations cause familial hypercholesterolemia through defective receptor binding, while common APOB polymorphisms modulate cholesterol levels through effects on LDL particle composition. The ultimate cholesterol outcome reflects the interplay between hepatic LDLR expression (affected by rs6511720), receptor degradation (PCSK9), and ligand quality (APOB).

The rs6910071 variant sits within an intron of TSBP1 (testis-expressed basic protein 1, formerly C6orf10), a gene embedded in the major histocompatibility complex (MHC) on chromosome 6p21. The MHC is the most densely associated genetic region for rheumatoid arthritis (RA), driven principally by HLA-DRB1 alleles encoding a five-amino-acid sequence called the shared epitope¹¹ shared epitope
A conserved sequence in the third hypervariable region of the HLA-DRβ chain (positions 70–74) that shapes the peptide-binding groove and is the dominant genetic risk factor for seropositive RA. Because rs6910071 sits in strong linkage disequilibrium with HLA-DRB1*04 shared-epitope haplotypes, it functions as a reliable GWAS tag for this high-risk haplotype block — catching much of the MHC-mediated RA susceptibility in a single testable SNP.

The Mechanism

TSBP1 itself is broadly expressed at low levels throughout adult tissues, with highest expression in the testis and modest expression in immune-relevant tissues including blood and lymph nodes. The gene activates protein kinase A (PKA) signaling and interacts with at least 14 genes implicated in autoimmune pathways. However, the primary clinical signal at rs6910071 is almost certainly indirect: the G allele tags a chromosomal haplotype block that includes HLA-DRB1*04:01 and related shared-epitope alleles, which together shape antigen presentation by class II MHC molecules to CD4+ T cells.

Shared-epitope HLA-DRB1 alleles promote autoimmunity through two mechanisms. First, they preferentially present citrullinated peptides — peptides carrying arginine residues enzymatically converted by PAD enzymes — leading to the anti-citrullinated protein antibodies (ACPA/anti-CCP) that are the serological hallmark of seropositive RA. Five amino-acid positions within HLA-DRB1, HLA-B, and HLA-DPB1 explain most of the MHC-wide RA association²² Five amino-acid positions within HLA-DRB1, HLA-B, and HLA-DPB1 explain most of the MHC-wide RA association
Fine-mapping study by Raychaudhuri et al. 2012 using imputed HLA alleles across 5,539 RA cases and 20,169 controls. Second, epigenetic dysregulation in the region may amplify risk: whole-blood bisulfite sequencing in RA patients identified differential hypomethylation at C6ORF10 CpG sites³³ differential hypomethylation at C6ORF10 CpG sites
Pearson correlation between C6ORF10 methylation and anti-CCP/RF levels was significantly negative, p<0.05, and the degree of hypomethylation correlated with serological risk markers anti-CCP and rheumatoid factor.

The Evidence

rs6910071 has been independently replicated in multiple large datasets. The most rigorous demonstration comes from a phenome-wide association study (PheWAS) across 29,349 Europeans in two biorepositories (MyCode/Geisinger and BioVU/Vanderbilt), which identified rs6910071 as the top replicating signal for rheumatoid arthritis and inflammatory polyarthropathies (pMETAL = 2.58 × 10⁻⁹⁴⁴ pMETAL = 2.58 × 10⁻⁹
60 cases/2,964 controls in MyCode; 81 cases/2,818 controls in BioVU). A separate genomic phenotype study identified the same variant as a novel locus for polymyalgia rheumatica⁵⁵ polymyalgia rheumatica
OR = 1.5, 95% CI 1.3–1.6, P = 1.3 × 10⁻¹⁰ in 413 PMR cases vs. 5,782 controls, a closely related inflammatory condition also strongly associated with HLA-DRB1*04.

A network analysis of 116 pleiotropic RA-associated genes identified C6orf10 as a hub gene⁶⁶ identified C6orf10 as a hub gene
Shared across nine autoimmune diseases including RA, psoriasis, SLE, multiple sclerosis, Graves' disease, and type 1 diabetes, consistent with the broader role of the HLA region in determining autoimmune susceptibility across organ systems. The G allele is notably more common in Europeans (~20%) than in African (~6%) or East Asian (~8%) populations, mirroring the higher prevalence of seropositive RA in northern European populations.

Practical Actions

Carriers of the G allele — particularly GG homozygotes — carry a meaningfully elevated prior probability of developing seropositive RA. The most evidence-based response to this genetic signal is early serological surveillance. ACPA (anti-CCP) and rheumatoid factor (RF) testing can identify preclinical seropositive RA years before joint damage begins; positive serology in the context of a high-risk genetic profile warrants rheumatology referral even before arthritis is clinically apparent.

Smoking is the primary modifiable environmental amplifier of shared-epitope RA risk: citrullination of lung proteins by cigarette smoke creates the neoantigens that, in shared-epitope carriers, trigger ACPA production. GG carriers who smoke face a combined gene-environment risk substantially larger than either factor alone.

Interactions

rs6910071 does not act in isolation. The strongest compound risk in RA comes from combining MHC-region HLA-DRB1 risk alleles (tagged by rs6910071) with non-HLA variants including PTPN22 R620W ([rs2476601 | The strongest non-HLA RA risk allele, increasing T-cell activation threshold]) and smoking exposure. When rs6910071-G is combined with rs2476601-A (PTPN22 R620W), the combined risk for seropositive RA exceeds either allele alone — a well-documented epistatic interaction where both T-cell and antigen-presentation pathways are simultaneously dysregulated.

The reduced folate carrier (RFC1, encoded by SLC19A1) is the principal route by which folates and antifolate drugs — including methotrexate — enter most human cells. Like any well-studied transporter gene, SLC19A1 carries a cluster of common variants that tend to travel together in haplotype blocks. rs12659 (Pro232Pro; 6318C>T on the coding strand) is one of four variants that define the second linkage disequilibrium block of SLC19A1, the others being rs1051266, rs1131596, and rs3788200.

The Mechanism

rs12659 itself is a synonymous variant¹¹ synonymous variant
A synonymous variant changes the DNA sequence but not the amino acid — the codon changes from one proline codon to another at position 232. Because the amino acid is unchanged, the variant does not directly alter transporter structure or function. Its clinical relevance comes primarily from its role as a haplotype tag: the A allele (plus-strand notation, corresponding to the coding-strand T allele) tags a specific version of the SLC19A1 gene that co-occurs with other functional variants in the same block, most prominently the transport-reducing rs1051266 T allele. This is why rs12659 signals in studies even though it encodes no protein change.

Synonymous variants can theoretically affect mRNA stability, splicing efficiency, or translation speed through codon-usage effects, and this possibility has been raised for SLC19A1 rs12659. However, direct experimental evidence for such a mechanism at this specific position is currently lacking.

The Evidence

Individual-SNP analysis in a pilot study of 100 Chinese rheumatoid arthritis patients receiving methotrexate found that rs12659 G allele carriers had significantly better clinical response: Cen et al. 2022²² Cen et al. 2022
Cen H et al. Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients. Pharmacogenomics Pers Med, 2022 reported RR=1.42 (95% CI=1.02–1.97, P=0.04) for EULAR good/moderate response under a dominant model (G/G + A/G vs A/A). Haplotype analysis in the same study showed the TGAA haplotype (carrying the A allele at rs12659 together with the rs1051266-T transport-reducing allele) was associated with worse MTX response (OR=0.37, 95% CI=0.14–0.98), indicating the haplotype effect is primarily driven by rs1051266.

In a separate study of 122 lung cancer cases vs 122 matched controls in Xuan Wei, China — a population with exceptionally high lung cancer rates attributed to indoor coal smoke — Shen et al. 2005³³ Shen et al. 2005
Shen M et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer, 2005 found the Pro232Pro C allele (plus-strand G allele) associated with increased lung cancer risk (OR=1.83, 95% CI=1.02–3.28). This finding requires caution: the sample was small, the population was exposed to an unusually potent carcinogen, and the result has not been replicated in non-coal-smoke contexts.

A PharmGKB pharmacogenomics summary⁴⁴ PharmGKB pharmacogenomics summary
Gong L et al. SLC19A1 Pharmacogenomics Summary. Pharmacogenet Genomics, 2010 notes that the Pro232Pro variant did not show a significant association with non-Hodgkin lymphoma across 1,000+ cases and controls, and showed a positive association with cervical carcinoma platinum-based chemotherapy response in one study, suggesting tissue- and drug-specific effects.

Practical Actions

Because rs12659 is a synonymous haplotype tag rather than a functional variant, it does not independently indicate any specific dietary or supplementation change. Its primary clinical value is as a marker that travels with the folate transport-modifying rs1051266 allele. Individuals homozygous for the A allele at rs12659 are very likely to also carry the rs1051266 T allele, meaning the folate transport considerations for that variant apply — principally, preferring methylfolate (5-MTHF) over synthetic folic acid and ensuring adequate cellular folate intake.

For patients taking methotrexate for rheumatoid arthritis, inflammatory bowel disease, or oncological indications, rs12659 A-allele homozygosity — as part of the TGAA haplotype context — may signal a need for closer monitoring of clinical response and folate status, since the linked rs1051266-T allele reduces cellular uptake of both folate and methotrexate.

Interactions

rs12659 is in strong linkage disequilibrium with rs1051266 (the functionally characterized G80A/His27Arg variant already profiled separately), rs1131596 (5'-UTR), and rs3788200 (intronic). In the four-SNP TGAA haplotype block, the dominant signal appears driven by rs1051266 — the transporter's known functional variant. Because this platform already profiles rs1051266 directly, rs12659 adds independent information only when an individual carries a discordant haplotype (rs12659-A without rs1051266-T, or vice versa), which is rare given the high LD between them.

Pathway-level interactions with MTHFR rs1801133 and MTHFD1 rs2236225 operate at the level of rs1051266's transport function, not rs12659 per se.

Deep inside your cells, lysosomes serve as the recycling centres responsible for breaking down worn-out proteins, lipids, and cellular debris. One enzyme is central to this process in neurons: glucocerebrosidase (GCase)¹¹ glucocerebrosidase (GCase)
encoded by the GBA1 gene, GCase converts glucosylceramide into glucose and ceramide — a routine lysosomal step whose impairment has outsized consequences for brain health. GBA variants are already established as the strongest known genetic risk factor for Parkinson's disease, and rs12752133 represents an independent intronic signal at the same locus with a large, replicated effect on the earliest detectable stage of this disease spectrum: REM sleep behavior disorder (RBD).

RBD — in which people physically act out vivid dreams during REM sleep — is not merely a sleep disorder. It is now recognised as a prodromal synucleinopathy marker, typically preceding Parkinson's disease diagnosis by a decade or more. Identifying your genetic risk profile at the GBA locus while still in this pre-motor window is the most actionable time to intervene.

The Mechanism

rs12752133 is an intronic variant located 94 nucleotides downstream of exon 11 in GBA1, at chromosomal position chr1:155,235,587 (GRCh38). The GBA gene is transcribed from the minus strand, so the plus-strand C→T change corresponds to a G→A transition on the coding strand within intron 11. The precise molecular mechanism by which this intronic position modulates disease risk is not yet fully characterized, but the leading hypothesis is that it alters pre-mRNA splicing efficiency or GBA1 expression levels, either independently or by influencing the regulatory architecture of the broader GBA1-GBAP1 locus region.

The downstream consequence is the same as for other GBA risk variants: reduced glucocerebrosidase activity impairs the autophagy-lysosomal pathway that dopaminergic neurons depend on to degrade misfolded proteins. When GCase activity falls, the glycolipid glucosylceramide accumulates. Glucosylceramide directly stabilises alpha-synuclein oligomers — the toxic species that seed Lewy body formation — while simultaneously inhibiting GCase further, creating a self-reinforcing vicious cycle²² self-reinforcing vicious cycle
Moors et al. Mov Disord 2016: lysosomal dysfunction and alpha-synuclein aggregation in post-mortem GBA-PD brain tissue between lysosomal failure and protein aggregation.

Importantly, rs12752133 and the N409S coding variant (rs76763715) are independent signals at the GBA locus — they sit 256 bp apart, likely in different functional elements of the gene, and their risk contributions are statistically separable in GWAS analysis.

The Evidence

The clearest evidence for rs12752133 comes from the largest genome-wide association study of REM sleep behavior disorder conducted to date³³ the largest genome-wide association study of REM sleep behavior disorder conducted to date
Krohn et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nature Communications, 2022. This meta-analysis enrolled 2,843 RBD cases and 139,636 controls, identifying five genome-wide significant loci: SNCA, GBA, TMEM175, INPP5F, and SCARB2. At the GBA locus, rs12752133-T reached p=5×10⁻¹⁴ with an odds ratio of 2.09 (95% CI 1.73–2.54) — a very large effect size for a GWAS finding. The GBA and TMEM175 loci were notable for being shared across all three main synucleinopathies studied: isolated RBD, Parkinson's disease with probable RBD, and Parkinson's disease without RBD, suggesting a fundamental biological role in the synucleinopathy continuum.

The broader case for GBA as the most consequential Parkinson's disease risk gene was established by the landmark multicenter NEJM study⁴⁴ the landmark multicenter NEJM study
Sidransky et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. NEJM, 2009, which analyzed 5,691 PD patients and 4,898 controls across 16 international centers and found an overall OR of 5.43 for any GBA mutation. The Nalls et al. 2019 meta-analysis⁵⁵ The Nalls et al. 2019 meta-analysis
Nalls et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease. Lancet Neurology, 2019 — spanning 37,688 cases and 1.4 million controls — confirmed GBA as one of 78 replicated genomic regions, underscoring the locus's biological centrality to PD pathogenesis.

Practical Actions

For T-allele carriers, the GBA mechanism suggests three actionable priorities: supporting lysosomal function and GCase activity, monitoring for prodromal RBD before motor symptoms appear, and avoiding environmental neurotoxins that compound dopaminergic vulnerability. The ambroxol pharmacological chaperone approach — currently in Phase 2 clinical trials targeting GBA-related neurodegeneration — represents the most mechanistically direct intervention available. Ambroxol binds misfolded GCase in the endoplasmic reticulum, stabilising its conformation to increase lysosomal delivery and enzyme activity; preclinical and open-label human data confirm it increases GCase activity and reduces CSF alpha-synuclein levels in GBA variant carriers.

Interactions

rs12752133 and the coding N409S variant (rs76763715) are independent signals at the GBA locus. Carriers of both may face compound impairment of GCase expression (via the intronic regulatory effect of rs12752133-T) and GCase protein folding (via the missense effect of N409S), potentially compounding lysosomal failure beyond either variant alone. This is a compound action candidate.

Within the broader synucleinopathy picture, GBA risk alleles interact with SNCA variants (rs356219, rs356182, rs2736990) — elevated alpha-synuclein from SNCA and impaired lysosomal clearance from GBA represent two independent drivers of Lewy body pathology converging on the same dopaminergic neuron population. The TMEM175 lysosomal potassium channel variant (rs76904798) is another locus identified in the same RBD GWAS that impairs lysosomal acidification — a second lysosomal mechanism compound action candidate alongside GBA.

The SLC30A8 gene encodes zinc transporter 8¹¹ zinc transporter 8
ZnT8 is a transmembrane protein that pumps zinc ions from the cytoplasm into insulin secretory granules inside pancreatic beta cells (ZnT8), a protein found almost exclusively in the insulin-producing beta cells of the pancreas. Its job is simple but critical: load zinc into the granules where insulin is stored. Zinc is essential for insulin to crystallize into its stable hexameric form — without adequate zinc, insulin is less stable, harder to store, and released less efficiently.

The rs13266634 variant changes a single amino acid at position 325 from arginine (encoded by the common C allele) to tryptophan (encoded by the T allele). This was one of the first type 2 diabetes risk loci identified by genome-wide association²² genome-wide association
Sladek R et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007, and it carries an unusual twist: the common allele (C, found in ~70% of people globally) is the risk allele, while the less common T allele is protective.

The Mechanism

ZnT8 sits in the membrane of insulin secretory granules and actively pumps zinc ions³³ zinc ions
Each insulin hexamer contains two Zn2+ ions at its core; roughly 70% of beta cell zinc resides in these granules into these compartments. Inside the granule, two zinc ions bind six insulin molecules to form a crystalline hexamer — the storage form of insulin. This crystallization increases storage capacity and protects insulin from premature degradation.

The Arg325 (C allele) and Trp325 (T allele) forms of ZnT8 differ in their zinc transport efficiency. Counterintuitively, the Arg325 version associated with the common C risk allele appears to transport zinc at higher capacity, yet carriers show impaired insulin processing⁴⁴ impaired insulin processing
Including elevated proinsulin-to-insulin ratios, suggesting that excess zinc granule loading may paradoxically interfere with the conversion of proinsulin to mature insulin and reduced first-phase insulin release. The Trp325 variant (T allele) has reduced transport activity but is associated with better insulin secretion dynamics.

This paradox was dramatically underscored when Flannick and colleagues⁵⁵ Flannick and colleagues
Flannick J et al. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet, 2014 discovered that rare complete loss-of-function mutations in SLC30A8 confer a striking 65% reduction in type 2 diabetes risk. This inverted the prevailing assumption that more ZnT8 activity equals better insulin function, and established ZnT8 inhibition as a potential therapeutic target.

The Evidence

The original GWAS⁶⁶ original GWAS
Sladek R et al. Nature, 2007 identified rs13266634 in a French cohort, and replication was swift. A meta-analysis of 46 studies⁷⁷ meta-analysis of 46 studies
Fan M et al. Association of SLC30A8 gene polymorphism with type 2 diabetes, evidence from 46 studies. Endocrine, 2016 encompassing 71,890 cases and 96,753 controls confirmed the association across European, Asian, and African populations with an odds ratio of approximately 1.15 per C allele (CC vs TT: OR ~1.53).

The EUGENE2 study⁸⁸ EUGENE2 study
Staiger H et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release. Diabetologia, 2008 showed that CC homozygotes had a 19% decrease in first-phase insulin release during intravenous glucose tolerance testing compared to T allele carriers, providing a functional mechanism linking genotype to diabetes risk.

Critically, the relationship between this variant and diabetes risk is modifiable by zinc status. Chu and colleagues⁹⁹ Chu and colleagues
Chu A et al. Interactions between zinc transporter-8 gene and plasma zinc concentrations for impaired glucose regulation and type 2 diabetes. Diabetes, 2014 found that each 10 ug/dL increase in plasma zinc was associated with 22% lower odds of type 2 diabetes in TT carriers, 17% lower in CT carriers, but only 7% lower in CC carriers — a significant gene-nutrient interaction.

A zinc supplementation trial¹⁰¹⁰ zinc supplementation trial
Maruthur NM et al. Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia, 2015 in 55 non-diabetic Amish individuals found that after 14 days of zinc supplementation (50 mg elemental zinc twice daily), carriers of the T allele experienced a 26% increase in early insulin response to glucose at 5 minutes compared to CC homozygotes — the first direct evidence that zinc supplementation can differentially improve beta cell function based on SLC30A8 genotype.

Practical Implications

This SNP sits at the intersection of genetics and nutrition. The key insight is that zinc status matters more for some genotypes than others. CC homozygotes have the highest baseline diabetes risk but show the smallest benefit from zinc optimization, while T allele carriers — who already have lower risk — get the most benefit from adequate zinc intake.

For everyone, ensuring adequate zinc intake supports insulin function. Good dietary sources include oysters, red meat, poultry, beans, nuts, and pumpkin seeds. For CC homozygotes, the focus should extend beyond zinc to broader metabolic health: maintaining a healthy weight, regular physical activity, and monitoring blood glucose are important given the modestly elevated diabetes risk.

Interactions

SLC30A8 rs13266634 interacts with other type 2 diabetes risk loci. The combination of the CC genotype here with TCF7L2 rs7903146 risk alleles (TT or CT) compounds overall diabetes risk through independent but converging pathways — SLC30A8 affecting insulin storage and release, TCF7L2 affecting beta cell development and incretin signaling. Individuals carrying risk alleles at both loci should be especially vigilant about metabolic health monitoring.

The SLC30A8 variant also influences ZnT8 autoantibody specificity in type 1 diabetes. The Arg325 (C allele) form is the dominant autoantibody target. While this does not change the type 2 diabetes risk interpretation, it adds a layer of immunological significance to this variant.

Adiponectin is the body's most abundant adipokine — a hormone secreted almost exclusively by adipose tissue¹¹ hormone secreted almost exclusively by adipose tissue
it activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces vascular inflammation that acts as a master regulator of insulin sensitivity, lipid metabolism, and metabolic inflammation. Low circulating adiponectin is one of the most consistent biomarkers of metabolic dysfunction, predicting insulin resistance, type 2 diabetes, NAFLD, and cardiovascular disease independently of BMI. The ADIPOQ gene on chromosome 3 encodes this protein, and variation across the locus — particularly in two linkage disequilibrium blocks spanning the promoter and intron 1 — accounts for a meaningful portion of inter-individual differences in circulating adiponectin.

rs16861205 (chr3:186,843,845 GRCh38) sits in intron 1 of ADIPOQ, within the same linkage disequilibrium block as the promoter variant rs266729. Because rs16861205 and rs266729 are in LD, some of their phenotypic associations overlap — but studies that genotyped both simultaneously demonstrate that rs16861205 has independent contributions to adiponectin dynamics and body weight regulation.

The Mechanism

Intronic variants in ADIPOQ intron 1 may influence gene expression via several mechanisms: disruption of intronic regulatory elements²² regulatory elements
sequences within introns that bind transcription factors or modulate chromatin accessibility, altered pre-mRNA splicing kinetics, or tagging of functional variants in the local LD block. rs16861205 (G>A) is an intron variant catalogued in dbSNP Build 157 with no direct protein-coding consequence. Its functional role is thought to be regulatory — either through direct intronic regulatory activity or as a haplotype tag for the broader LD block 1, which contains the promoter.

The haplotype block containing rs16861205 and rs266729 spans the region approximately −14,811 to −4,120 base pairs relative to the ADIPOQ transcription start, covering the proximal promoter and intron 1. Variants in this block collectively influence ADIPOQ transcriptional activity and circulating adiponectin levels. Because rs16861205 participates in this block, its A allele may tag a local chromatin state that alters adiponectin expression — and the gender-specific effects observed in African American cohorts suggest the regulatory influence may be modulated by sex hormone signalling on ADIPOQ transcription.

The Evidence

The most informative data come from two independent cohorts. In the Finnish Diabetes Prevention Study³³ Finnish Diabetes Prevention Study
n=507 overweight subjects with impaired glucose tolerance randomised to intensive lifestyle intervention vs control; Siitonen et al. 2011, rs16861205 was significantly associated with baseline body weight (GG carriers: 87.7 kg vs. GA/AA carriers: 84.3 kg, dominant model p=0.006) and with 4-year longitudinal weight change (additive p=0.028, dominant p=0.008). Strikingly, the A allele was associated with a greater increase in serum adiponectin concentrations over 4 years (additive p=0.040, dominant p=0.014), particularly among participants who lost weight during the first year of intervention. This suggests the A allele may reflect a distinct regulatory state in which adiponectin production is more responsive to weight loss.

A contrasting pattern was observed in the Jackson Heart Study⁴⁴ Jackson Heart Study
n=2,968 African American adults (1,131 men, 1,837 women); Davis et al. 2015 — the largest population-specific analysis of rs16861205 to date. In women, the A allele was significantly associated with lower circulating adiponectin in the fully adjusted model (beta=−0.13, SE=0.05, p=0.003). No significant association was found in men (beta=−0.11, SE=0.061, p=0.074). A gender-stratified haplotype analysis Yansane et al. 2015⁵⁵ Yansane et al. 2015 confirmed that rs16861205 participates in a haplotype block (with rs6444174, rs1403697, and rs7641507) that shows significant effects on adiponectin in women but not men.

Taken together, the evidence points to rs16861205 as a variant that modulates adiponectin levels in a sex-specific and context-dependent way. The A allele appears to reduce baseline adiponectin in women (particularly African American women) while potentially conferring greater adiponectin responsiveness to weight loss intervention.

Practical Actions

For carriers of the A allele — particularly women — the primary concern is ensuring circulating adiponectin remains within the protective range (>8 µg/mL in women,

6 µg/mL in men). The most evidence-based dietary intervention for raising adiponectin is omega-3 fatty acids: a meta-analysis of 43 randomised trials with 3,434 participants found that EPA and DHA supplementation significantly increases adiponectin, with the largest effects in individuals with low baseline levels. Replacing dietary saturated fat with monounsaturated and polyunsaturated fats activates PPARgamma in adipocytes, stimulating ADIPOQ transcription regardless of intronic genotype.

For AA homozygotes and AG women with metabolic risk factors, measuring serum adiponectin directly provides the most actionable information — it reveals whether the regulatory variant is actually suppressing output to clinically meaningful levels, and it allows monitoring of dietary intervention response over time.

Interactions

rs16861205 is in the same LD block as rs266729, the well-characterised ADIPOQ promoter variant on the platform. The combined haplotype effect of LD block 1 (rs266729 + rs16861205) on adiponectin is likely stronger than either SNP alone, but the direction of the interaction requires haplotype-level analysis. Users carrying the rs266729 G risk allele alongside the rs16861205 A allele may have the most pronounced reduction in adiponectin signalling from this LD block.

rs182052 (ADIPOQ −10066G>A), also in the platform, shows a diet-genotype interaction with monounsaturated fat intake: rs182052 G/G homozygotes increase adiponectin on a high-MUFA diet while A-allele carriers do not — making fat quality a particularly relevant modifiable factor for the broader ADIPOQ LD block.